AMRN Amarin Corporation plc - American Depositary Shares
$14,37
Preço · Ago 19, 2026
Fundamentais a partir de Jul 29, 2026
Intervalo 52 Semanas
$13–$21
18% of range
Classificação do Analista
HOLD
6 analysts
Preço-Alvo
$12
P/E (TTM)
-159.7
ROE
-8.4%
Margem de Lucro Líquido
-18.2%
Sobre Amarin Corporation plc - American Depositary Shares Visão geral da empresa da Wikipedia
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
Ler mais
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.
History
Amarin Corporation plc (formerly Ethical Holdings plc) was originally incorporated in England as a private limited company on March 1, 1989, and later re-registered as a public company on March 19, 1993. In 2002, the company suffered losses worth $37 million; 2003 losses exceeded $19 million. As of 2005, it was developing neurology drugs. It developed Miraxion to treat serious hereditary neurodegenerative disease.
In December 2007, Amarin acquired Ester Neurosciences Limited for US$8.1 million. In 2011, CEO Joe Zakrzewski said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.
Products and development
Vascepa (USA) / Vazkepa (EU)
Amarin´s sole product VASCEPA® came on the market in 2013 for triglyceride levels >=500 milligrams per deciliter. In December 2019, the FDA approved "...the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease....Vascepa is the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy.
Furthermore, VASCEPA® is in use in clinical trials by 3rd parties to see, if it has an effect on Alzheimer, Colon Cancer, Nonalcoholic Steatohepatitis (NASH), and other diseases.
HLS Therapeutics, Amarin´s license partner in Canada, presented results of their COVID-19 clinical trial for Vascepa at National Lipid Association Scientific Sessions 2020, December 12. The results demonstrated a 25% reduction of hs-CRP, a biomarker for inflammation. Most people with COVID-19 die, because of a cytokine storm, which causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines. Two more COVID-19 studies are actually running with Vascepa to validate and proof further benefits.
On January 28, the Committee for Medicinal Products for Human Use gave a positive recommendation for Vazcepa (its name in the EU), which the European Commission finally approved on March 30.
Patent disputes
On March 30, 2020, the designated patent judge in the U.S. District Court for the District of Nevada, Miranda Du, ruled for generic-drug makers Hikma Pharmaceuticals and Dr. Reddy's Laboratories in a lawsuit with Amarin over patents on Amarin's drug, Vascepa. Soon after, on April 2, 2020, Amarin filed an appeal of the ruling. The appeal was lost and an en-banc was also not granted, afterwards. On November 30, three weeks after Hikma Pharmaceuticals started the distribution of their generic version of Vascepa, Amarin filed a complaint of patent infringement against Hikma. On February 11, 2021, Amarin filed a petition for certiorari with the US Supreme Court. On June 21, 2021, the petition was denied.
== Finance ==
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
AMRN Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$14.37
Capitalização de Mercado
$5.98B
P/E (TTM)
-159.7
EPS (TTM)
$-0.09
Receita (TTM)
$214M
Rendimento div.
—
ROE
-8.4%
Dívida/Capital
—
Intervalo 52 Semanas
$13 – $21
AMRN Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$214M
2016-12-31
→
2025-12-31
EPS
$-0.09
2016-12-31
→
2025-12-31
Fluxo de caixa livre
—
2016-12-31
→
2020-12-31
Margens
-18.2%
2016-12-31
→
2025-12-31
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
AMRN
Mediana de Pares
P/E (TTM)
-159.7
55.9
P/S (TTM)
28.0
5.5
P/B
13.0
1.8
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
AMRN
Mediana de Pares
Gross Margin (Margem Bruta)
56.6%
63.8%
Operating Margin (Margem Operacional)
-23.5%
—
Net Profit Margin (Margem de Lucro Líquido)
-18.2%
-14.2%
ROA
-5.7%
-4.2%
ROE
-8.4%
-6.0%
ROIC
-11.8%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
AMRN
Mediana de Pares
Current Ratio (Índice de liquidez corrente)
3.3
3.7
Quick Ratio (Índice de Liquidez Seca)
2.2
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
AMRN
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
-6.6%
—
Revenue CAGR 3Y (CAGR Receita 3A)
-16.7%
—
Revenue CAGR 5Y (CAGR Receita 5A)
-19.0%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
AMRN
Mediana de Pares
AMRN Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
VENDA
6 analistas
- Compra forte 0 0,0%
- Compra 0 0,0%
- Manter 2 33,3%
- Venda 2 33,3%
- Venda forte 2 33,3%
Preço-alvo de 12 meses
1 analistas · 2026-08-15
Mín
$12.00
Máx
$12.00
Alvo mediano
$12.00
-16,5%
Alvo médio
$12.00
-16,5%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
0.20%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $0.04 | $-0.01 | 0.05% |
| 31 de Março de 2026 | $-0.09 | $0.09 | -0.18% |
| 31 de Dezembro de 2025 | $0.01 | $0.00 | 0.01% |
| 30 de Setembro de 2025 | $0.08 | $-0.58 | 0.66% |
| 30 de Junho de 2025 | $0.66 | $-0.18 | 0.84% |
| 31 de Março de 2025 | $-0.76 | $-0.58 | -0.18% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| AMRN | $5.81B | -155.1 | -6.6% | -18.2% | -8.4% | 56.6% |
| ALKS | $4.63B | 19.6 | -5.2% | 16.4% | 14.0% | — |
| PRTA | $514M | -2.1 | -92.8% | -2520.6% | -63.6% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 18
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $214M | $229M | $307M | $369M | $583M | $614M | $430M | $229M | $181M | $130M | $82M | $54M | |
| Cost of Revenue | · | · | · | · | $121M | $131M | $96M | $55M | $45M | $34M | $28M | $20M | |
| Gross Profit | $121M | $81M | $166M | $242M | $462M | $483M | $334M | $175M | $136M | $96M | $54M | $34M | |
| R&D Expense | $20M | $21M | $22M | $30M | $29M | $39M | $34M | $56M | $47M | $50M | $51M | $50M | |
| SG&A Expense | $115M | $152M | $200M | $304M | $408M | $463M | $324M | $227M | $135M | $111M | $101M | $79M | |
| Operating Expenses | $171M | $173M | $233M | $348M | $451M | $502M | $358M | $283M | $182M | $161M | $152M | $130M | |
| Operating Income | $-50M | $-92M | $-68M | $-106M | $11M | $-20M | $-24M | $-108M | $-46M | $-66M | $-98M | $-96M | |
| Interest Expense | $7.0K | $7.0K | $8.0K | $15.0K | $129.0K | $3M | $7M | $9M | $10M | $19M | $20M | $19M | |
| Interest Income | $11M | $13M | $12M | $3M | $1M | $5M | $8M | $1M | $429.0K | $234.0K | $132.0K | $96.0K | |
| Other Non-op | $3M | $1M | $2M | $-740.0K | $-302.0K | $104.0K | $-75.0K | $-326.0K | $74.0K | $-482.0K | $-228.0K | $4M | |
| Pretax Income | $-36M | $-77M | $-54M | $-104M | $11M | $-17M | $-22M | $-116M | $-55M | $-76M | $-118M | $-59M | |
| Income Tax | $3M | $5M | $5M | $2M | $4M | $745.0K | $164.0K | $96.0K | $13M | $10M | $-3M | $-3M | |
| Net Income | $-39M | $-82M | $-59M | $-106M | $8M | $-18M | $-23M | $-116M | $-68M | $-86M | $-115M | $-56M | |
| EPS (Basic) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 | $-0.05 | $-0.07 | $-0.39 | $-0.25 | $-0.41 | $-0.83 | $-0.32 | |
| EPS (Diluted) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 | $-0.05 | $-0.07 | $-0.39 | $-0.25 | $-0.41 | $-0.83 | $-0.36 | |
| Shares (Basic) | 414,984,000 | 410,937,000 | 407,655,000 | 401,155,000 | 395,992,000 | 381,759,000 | 342,538,000 | 297,237,000 | 270,652,000 | 211,874,000 | 180,654,000 | 173,719,000 | |
| Shares (Diluted) | 414,984,000 | 410,937,000 | 407,655,000 | 401,155,000 | 402,480,000 | 381,759,000 | 342,538,000 | 297,237,000 | 270,652,000 | 211,874,000 | 180,654,000 | 173,824,000 | |
| EBITDA | $-50M | $-92M | $-68M | · | · | $-20M | · | $-108M | $-46M | $-66M | $-98M | $-96M |
Balanço Patrimonial 27
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $135M | $121M | $199M | $218M | $219M | $187M | $645M | $249M | $74M | $98M | $107M | $120M | |
| Short-term Investments | $168M | $173M | $121M | $92M | $235M | $314M | · | · | · | · | · | · | |
| Receivables | $127M | $122M | $134M | $131M | $164M | $155M | $116M | $67M | $45M | $20M | $14M | $8M | |
| Inventory | $196M | $166M | $259M | $229M | $235M | $189M | $77M | $58M | $30M | $21M | $19M | $14M | |
| Prepaid Expense | $24M | $13M | $12M | $19M | $22M | $31M | $13M | $3M | $3M | $7M | $3M | $3M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| Current Assets | $650M | $595M | $725M | $689M | $879M | $879M | $855M | $378M | $153M | $146M | $144M | $145M | |
| PP&E (Net) | $12.0K | $16.0K | $114.0K | $874.0K | $1M | $2M | $2M | $63.0K | $28.0K | $78.0K | $243.0K | $381.0K | |
| PP&E (Gross) | $1M | $1M | $1M | $3M | $3M | $4M | $3M | $902.0K | $844.0K | $821.0K | $997.0K | $969.0K | |
| Accum. Depreciation | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $839.0K | $816.0K | $755.0K | $754.0K | $588.0K | |
| Intangibles | $13M | $16M | $19M | $22M | $24M | $14M | $15M | $7M | $8M | $9M | $9M | $10M | |
| Other Non-current Assets | $1M | $1M | $1M | $458.0K | $456.0K | $432.0K | $1M | $174.0K | $174.0K | $741.0K | $174.0K | $3M | |
| Total Assets | $671M | $685M | $832M | $886M | $1.07B | $966M | $882M | $386M | $162M | $167M | $173M | $171M | |
| Accounts Payable | $45M | $40M | $53M | $65M | $115M | $106M | $50M | $38M | $25M | $6M | $11M | $9M | |
| Current Liabilities | $194M | $180M | $259M | $259M | $371M | $307M | $242M | $157M | $109M | $76M | $51M | $40M | |
| Capital Leases | $6M | $8M | $9M | $10M | $9M | $9M | $9M | · | · | · | · | · | |
| Other Non-current Liabilities | $11M | $12M | $9M | $8M | $8M | $6M | $4M | $11M | $1M | $710.0K | $335.0K | $386.0K | |
| Total Liabilities | $211M | $199M | $280M | $291M | $401M | $339M | $274M | $233M | $227M | $176M | $301M | $260M | |
| Long-term Debt | · | · | · | · | · | · | $50M | $80M | $92M | $94M | $92M | $105M | |
| Total Debt | · | · | · | · | · | $0 | · | $80M | $93M | $101M | $106M | $105M | |
| Common Stock | $310M | $305M | $303M | $299M | $294M | $290M | $269M | $247M | $209M | $207M | $150M | $143M | |
| Paid-in Capital | $1.92B | $1.91B | $1.90B | $1.89B | $1.86B | $1.82B | $1.76B | $1.28B | $978M | · | · | · | |
| Retained Earnings | $-1.71B | $-1.67B | $-1.59B | $-1.53B | $-1.42B | $-1.43B | $-1.41B | $-1.39B | $-1.27B | $-1.20B | $-1.12B | $-970M | |
| Treasury Stock | $67M | $65M | $64M | $62M | $61M | $51M | $36M | $10M | $4M | $1M | $411.0K | $217.0K | |
| Stockholders' Equity | $459M | $486M | $552M | $595M | $667M | $628M | $608M | $152M | $-65M | $-9M | $-129M | $-88M | |
| Liabilities + Equity | $671M | $685M | $832M | $886M | $1.07B | $966M | $882M | $386M | $162M | $167M | $173M | $171M | |
| Shares Outstanding | 416,214,102 | 411,584,851 | 408,824,093 | 408,824,093 | 396,598,008 | 392,538,081 | 360,103,901 | 325,850,013 | 271,022,011 | 269,363,696 | 183,403,263 | 174,590,372 |
Fluxo de Caixa 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $23.0K | $62.0K | $138.0K | $166.0K | $198.0K | |
| Stock-based Comp | $14M | $18M | $16M | $26M | $37M | $46M | $31M | $19M | $14M | $14M | $14M | $9M | |
| Deferred Tax | · | · | · | · | · | · | · | · | $11M | $9M | $-4M | $-4M | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $2M | $1M | $679.0K | $646.0K | $646.0K | $645.0K | $646.0K | $646.0K | |
| Restructuring | $36M | $0 | $11M | $14M | $14M | · | · | · | · | · | · | · | |
| Operating Cash Flow | $7M | $-31M | $7M | $-180M | $-67M | $-22M | $-9M | $-95M | $-33M | $-72M | $-84M | $-75M | |
| CapEx | · | · | · | · | · | $252.0K | $2M | $58.0K | $12.0K | $21.0K | $28.0K | · | |
| Investing Cash Flow | $9M | $-46M | $-26M | $175M | $104M | $-377M | $-2M | $-58.0K | $-12.0K | $-21.0K | · | · | |
| Net Debt Issued | · | · | · | · | · | $-50M | · | $-15M | $-3M | · | · | · | |
| Stock Issued | · | · | · | · | · | · | $440M | $265M | · | $65M | · | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | $194.0K | · | |
| Net Stock Activity | · | · | · | · | · | · | · | $265M | · | $65M | $-194.0K | · | |
| Financing Cash Flow | $-2M | $-1M | $230.0K | $-379.0K | $-5M | $-59M | $410M | $271M | $8M | $63M | · | · | |
| Net Change in Cash | $14M | $-78M | $-18M | $-5M | $32M | $-458M | $398M | $176M | $-25M | $-9M | $-13M | $-72M | |
| Taxes Paid | $1M | $4M | $2M | $-2M | $4M | $-207.0K | $-67.0K | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | $-22M | · | $-95M | $-33M | $-72M | $-85M | · | |
| Levered FCF | · | · | · | · | · | $-25M | · | $-104M | $-45M | $-93M | $-104M | · |
Lucratividade 8
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.6% | 35.6% | 53.9% | · | · | 78.6% | · | 76.2% | 75.2% | 73.6% | 65.9% | 62.2% | |
| Operating Margin | -23.5% | -40.2% | -22.0% | · | · | -3.2% | · | -47.2% | -25.1% | -50.4% | -120.1% | -177.0% | |
| Net Margin | -18.2% | -35.9% | -19.3% | · | · | -2.9% | · | -50.8% | -37.5% | -66.4% | -140.9% | -104.0% | |
| Pretax Margin | -16.9% | -33.8% | -17.5% | · | · | -2.8% | · | -50.8% | -30.3% | -58.7% | -144.7% | -109.2% | |
| EBITDA Margin | -23.5% | -40.2% | -22.0% | · | · | -3.2% | · | -47.2% | -25.1% | -50.4% | -120.1% | -177.0% | |
| ROA | -5.7% | -10.8% | -6.9% | · | · | -1.9% | · | -42.5% | -41.3% | -50.8% | -66.9% | -26.6% | |
| ROE | -8.4% | -16.2% | -10.7% | · | · | -2.9% | · | -234.1% | 183.0% | 124.9% | 105.9% | 92.2% | |
| ROIC | -11.8% | -20.1% | -13.5% | · | · | -3.3% | · | -46.6% | -200.8% | -80.6% | 417.0% | -551.6% |
Liquidez e Solvência 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.3 | 2.8 | · | · | 2.9 | · | 2.4 | 1.4 | 1.9 | 2.8 | 3.6 | |
| Quick Ratio | 2.2 | 2.3 | 1.8 | · | · | 2.1 | · | 2.0 | 1.1 | 1.6 | 2.4 | 3.2 | |
| Debt / Equity | · | · | · | · | · | 0.0 | · | 0.5 | -1.4 | -11.2 | -0.8 | -1.2 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 0.3 | -1.1 | -9.4 | -0.7 | -1.0 | |
| Interest Coverage | -7167.1 | -13113.9 | -8448.5 | · | · | -7.5 | · | -12.2 | -4.7 | -3.5 | -4.9 | -5.2 |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | 0.4 | · | · | 0.7 | · | 0.8 | 1.1 | 0.8 | 0.5 | 0.3 | |
| Inventory Turnover | · | · | · | · | · | 1.0 | · | 1.2 | 1.8 | 1.7 | 1.7 | 1.2 | |
| Receivables Turnover | 1.7 | 1.8 | 2.3 | · | · | 4.5 | · | 4.1 | 5.5 | 7.7 | 7.5 | 9.4 |
Taxas de Crescimento 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -6.6% | -25.5% | -16.9% | -36.7% | -5.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -16.7% | -26.8% | -20.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -19.0% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 14
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $214M | $229M | $307M | $369M | $583M | $614M | $430M | $229M | $181M | $130M | $82M | $54M | |
| Net Income TTM | $-39M | $-82M | $-59M | $-106M | $8M | $-18M | $-23M | $-116M | $-68M | $-86M | $-115M | $-56M | |
| Market Cap | $5.81B | $4.03B | $7.11B | · | · | $38.39B | · | $88.70B | $21.74B | $16.59B | $6.93B | $3.42B | |
| Enterprise Value | · | · | · | · | · | $37.89B | · | $88.53B | $21.76B | $16.60B | $6.93B | $3.41B | |
| P/E | -155.1 | -49.0 | -116.0 | -93.1 | 3370.0 | -1956.0 | -6125.7 | -697.9 | -320.8 | -150.2 | -45.5 | -54.4 | |
| P/S | 27.2 | 17.6 | 23.2 | · | · | 62.5 | · | 387.0 | 120.0 | 127.6 | 84.8 | 63.1 | |
| P/B | 12.7 | 8.3 | 12.9 | · | · | 61.2 | · | 582.3 | -333.9 | -1831.8 | -53.7 | -38.7 | |
| P / Tangible Book | 13.0 | 8.6 | 13.4 | 17.1 | 41.5 | 62.6 | · | · | · | · | · | · | |
| P / Cash Flow | 863.6 | -130.0 | 1033.9 | · | · | -1765.4 | · | -936.6 | -661.9 | -231.0 | -81.8 | -47.3 | |
| P / FCF | · | · | · | · | · | -1745.2 | · | -936.0 | -661.7 | -231.0 | -81.8 | · | |
| EV / EBITDA | · | · | · | · | · | -1927.7 | · | -818.0 | -477.6 | -252.9 | -70.6 | -35.5 | |
| EV / FCF | · | · | · | · | · | -1722.4 | · | -934.2 | -662.3 | -231.0 | -81.8 | · | |
| EV / Revenue | · | · | · | · | · | 61.7 | · | 386.2 | 120.1 | 127.6 | 84.8 | 62.9 | |
| Earnings Yield | -0.64% | -2.0% | -0.86% | -1.1% | 0.03% | -0.05% | -0.02% | -0.14% | -0.31% | -0.67% | -2.2% | -1.8% |
Demonstração de Resultados 16
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42M | $45M | $49M | $50M | $73M | $42M | $62M | $42M | $67M | $57M | $75M | $66M | $80M | $86M | $90M | $90M | |
| Gross Profit | $15M | $18M | $23M | $22M | $50M | $25M | $-10M | $16M | $43M | $32M | $45M | $30M | $43M | $48M | $64M | $63M | |
| R&D Expense | $5M | $5M | $5M | $4M | $5M | $5M | $6M | $5M | $5M | $6M | $6M | $5M | $6M | $6M | $5M | $6M | |
| SG&A Expense | $22M | $21M | $20M | $20M | $39M | $37M | $37M | $37M | $39M | $40M | $44M | $45M | $51M | $60M | $68M | $59M | |
| Operating Expenses | $27M | $29M | $29M | $33M | $66M | $42M | $43M | $41M | $43M | $45M | $50M | $51M | $67M | $65M | $73M | $68M | |
| Operating Income | $-12M | $-11M | $-6M | $-11M | $-16M | $-17M | $-53M | $-25M | $-524.0K | $-14M | $-5M | $-21M | $-24M | $-17M | $-10M | $-5M | |
| Interest Income | $3M | $2M | · | · | $3M | $3M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $1M | $188.0K | $3M | $205.0K | $-85.0K | $253.0K | $-754.0K | $265.0K | $145.0K | $2M | $-1M | $-575.0K | $3M | $624.0K | $1M | $511.0K | |
| Pretax Income | $-8M | $-9M | $-853.0K | $-8M | $-13M | $-14M | $-50M | $-22M | $3M | $-9M | $-2M | $-19M | $-18M | $-14M | $-7M | $-4M | |
| Income Tax | $-219.0K | $2M | $371.0K | $-377.0K | $689.0K | $2M | $-1M | $4M | $1M | $1M | $3M | $501.0K | $-355.0K | $2M | $-8M | $1M | |
| Net Income | $-8M | $-11M | $-1M | $-8M | $-14M | $-16M | $-49M | $-25M | $2M | $-10M | $-6M | $-19M | $-18M | $-16M | $856.0K | $-5M | |
| EPS (Basic) | $-0.02 | $-0.03 | $0.00 | $-0.02 | $-0.03 | $-0.04 | $-0.12 | $-0.06 | $0.00 | $-0.02 | $-0.02 | $-0.05 | $-0.04 | $-0.04 | $0.01 | $-0.01 | |
| EPS (Diluted) | $-0.02 | $-0.03 | $0.00 | $-0.02 | $-0.03 | $-0.04 | $-0.12 | $-0.06 | $0.00 | $-0.02 | $-0.02 | $-0.05 | $-0.04 | $-0.04 | $0.01 | $-0.01 | |
| Shares (Basic) | 416,444,000 | 419,054,000 | -828,446,000 | 415,531,000 | 414,477,000 | 413,422,000 | -821,210,000 | 411,150,000 | 410,851,000 | 410,146,000 | -814,787,000 | 408,417,000 | 407,848,000 | 406,177,000 | -799,451,000 | 404,614,000 | |
| Shares (Diluted) | 416,444,000 | 419,054,000 | -828,446,000 | 415,531,000 | 414,477,000 | 413,422,000 | -821,754,000 | 411,150,000 | 411,395,000 | 410,146,000 | -814,787,000 | 408,417,000 | 407,848,000 | 406,177,000 | -799,451,000 | 404,614,000 | |
| EBITDA | $-12M | $-11M | · | $-11M | $-16M | $-17M | · | $-25M | $-524.0K | $-14M | · | $-21M | $-24M | $-17M | · | $-5M |
Balanço Patrimonial 24
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $144M | $131M | $135M | $123M | $148M | $120M | $121M | $157M | $216M | $214M | · | $271M | $233M | $191M | · | $240M | |
| Short-term Investments | $171M | $177M | $168M | $164M | $151M | $162M | $173M | $149M | $91M | $94M | · | $50M | $80M | $113M | · | $63M | |
| Receivables | $93M | $108M | $127M | $127M | $119M | $107M | $122M | $113M | $124M | $116M | · | $122M | $123M | $133M | · | $123M | |
| Inventory | $164M | $184M | $196M | $185M | $171M | $159M | $166M | $224M | $239M | $255M | · | $254M | $227M | $226M | · | $228M | |
| Prepaid Expense | $31M | $26M | $24M | $29M | $17M | $25M | $13M | $7M | $32M | $8M | · | $19M | $43M | $20M | · | $28M | |
| Current Assets | $603M | $626M | $650M | $628M | $607M | $573M | $595M | $650M | $702M | $688M | · | $718M | $706M | $684M | · | $687M | |
| PP&E (Net) | · | · | $12.0K | $13.0K | $14.0K | $15.0K | $16.0K | $24.0K | $49.0K | $81.0K | · | $147.0K | $179.0K | $187.0K | · | $999.0K | |
| PP&E (Gross) | · | · | $1M | · | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $1M | · | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $12M | $13M | $13M | $14M | $15M | $16M | $16M | $17M | $18M | $19M | · | $20M | $20M | $21M | · | $22M | |
| Other Non-current Assets | $4M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $2M | $2M | · | $456.0K | |
| Total Assets | $624M | $646M | $671M | $660M | $670M | $656M | $685M | $751M | $800M | $790M | · | $839M | $860M | $860M | · | $908M | |
| Accounts Payable | $19M | $48M | $45M | $37M | $45M | $46M | $40M | $41M | $54M | $68M | · | $53M | $54M | $59M | · | $93M | |
| Current Liabilities | $164M | $180M | $194M | $182M | $186M | $162M | $180M | $202M | $231M | $224M | · | $267M | $271M | $244M | · | $287M | |
| Capital Leases | $5M | $6M | $6M | $7M | $7M | $8M | $8M | $8M | $8M | $8M | · | $9M | $9M | $10M | · | $10M | |
| Other Non-current Liabilities | $11M | $11M | $11M | $12M | $12M | $12M | $12M | $9M | $9M | $9M | · | $7M | $7M | $9M | · | $10M | |
| Total Liabilities | $181M | $196M | $211M | $201M | $205M | $182M | $199M | $219M | $248M | $244M | · | $286M | $291M | $275M | · | $320M | |
| Common Stock | $315M | $314M | $310M | $310M | $309M | $308M | $305M | $305M | $305M | $305M | · | $302M | $302M | $301M | · | $299M | |
| Paid-in Capital | $1.92B | $1.92B | $1.92B | $1.92B | $1.92B | $1.92B | $1.91B | $1.91B | $1.91B | $1.90B | · | $1.90B | $1.89B | $1.89B | · | $1.88B | |
| Retained Earnings | $-1.73B | $-1.72B | $-1.71B | $-1.71B | $-1.70B | $-1.68B | $-1.67B | $-1.62B | $-1.59B | $-1.60B | · | $-1.58B | $-1.56B | $-1.54B | · | $-1.53B | |
| Treasury Stock | $69M | $69M | $67M | $67M | $67M | $66M | $65M | $65M | $65M | $65M | · | $64M | $63M | $63M | · | $62M | |
| Stockholders' Equity | $444M | $449M | $459M | $459M | $465M | $474M | $486M | $531M | $552M | $546M | $552M | $553M | $569M | $585M | $595M | $588M | |
| Liabilities + Equity | $624M | $646M | $671M | $660M | $670M | $656M | $685M | $751M | $800M | $790M | · | $839M | $860M | $860M | · | $908M | |
| Shares Outstanding | 420,044,022 | 419,594,602 | 416,214,102 | 415,965,977 | 415,401,497 | 414,365,189 | 411,584,851 | 411,261,678 | 411,113,770 | 410,735,780 | · | 408,551,020 | 408,133,807 | 407,265,944 | 408,824,093 | 403,828,955 |
Fluxo de Caixa 9
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $6M | $4M | $3M | $5M | $4M | $5M | $5M | $4M | $2M | $6M | $7M | $5M | |
| Amort. of Intangibles | $636.0K | $637.0K | $701.0K | $866.0K | $728.0K | $729.0K | $729.0K | $728.0K | $729.0K | $729.0K | $701.0K | $701.0K | $701.0K | $702.0K | $636.0K | $636.0K | |
| Restructuring | $40.0K | $3M | $4M | $9M | $23M | · | · | · | · | · | $229.0K | $711.0K | $10M | · | $-180.0K | $3M | |
| Operating Cash Flow | $7M | $6M | $15M | $-13M | $17M | $-12M | $-13M | $-2M | $-3M | $-13M | $-645.0K | $7M | $7M | $-7M | $2M | $-18M | |
| Investing Cash Flow | $6M | $-8M | $-4M | $-12M | $12M | $12M | $-23M | $-57M | $5M | $29M | $-71M | $31M | $34M | $-20M | $-28M | $31M | |
| Stock Issued | · | · | · | · | · | · | · | $0 | · | · | · | $0 | · | · | · | $0 | |
| Financing Cash Flow | $-247.0K | $-2M | $-4.0K | $-248.0K | $-663.0K | $-1M | $17.0K | $-68.0K | $34.0K | $-1M | $83.0K | $-277.0K | $60.0K | $364.0K | $38.0K | $-156.0K | |
| Net Change in Cash | $12M | $-4M | $12M | $-25M | $28M | $-2M | $-36M | $-59M | $2M | $15M | $-72M | $38M | $42M | $-26M | $-26M | $12M | |
| Taxes Paid | $1M | $2M | $1M | $-1.0K | $-169.0K | $22.0K | $6M | $-1M | $-698.0K | $29.0K | $3M | $-432.0K | $-633.0K | $38.0K | $-292.0K | $622.0K |
Lucratividade 8
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.5% | 39.4% | · | 44.7% | 69.2% | 59.8% | · | 38.5% | 63.4% | 56.5% | · | 45.1% | 53.2% | 55.8% | · | 69.9% | |
| Operating Margin | -28.4% | -25.1% | · | -22.4% | -22.0% | -39.9% | · | -59.5% | -0.78% | -24.0% | · | -32.5% | -29.9% | -20.2% | · | -5.7% | |
| Net Margin | -18.1% | -23.3% | · | -15.6% | -19.4% | -37.4% | · | -59.4% | 2.3% | -17.6% | · | -29.2% | -21.9% | -19.1% | · | -5.7% | |
| Pretax Margin | -18.6% | -19.3% | · | -16.3% | -18.5% | -32.4% | · | -50.9% | 4.3% | -15.3% | · | -28.5% | -22.4% | -16.9% | · | -4.3% | |
| EBITDA Margin | -28.4% | -25.1% | · | -22.4% | -22.0% | -39.9% | · | -59.5% | -0.78% | -24.0% | · | -32.5% | -29.9% | -20.2% | · | -5.7% | |
| ROA | -1.2% | -1.6% | · | -1.1% | -1.9% | -2.2% | · | -3.2% | 0.18% | -1.2% | · | -2.2% | -1.9% | -1.8% | · | -0.53% | |
| ROE | -1.7% | -2.3% | · | -1.6% | -2.8% | -3.1% | · | -4.6% | 0.27% | -1.8% | · | -3.4% | -3.1% | -2.7% | · | -0.84% | |
| ROIC | -2.6% | -3.0% | · | -2.3% | -3.6% | -4.1% | · | -5.5% | -0.05% | -2.9% | · | -4.0% | -4.1% | -3.4% | · | -1.2% |
Liquidez e Solvência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 3.5 | · | 3.4 | 3.3 | 3.5 | · | 3.2 | 3.0 | 3.1 | · | 2.7 | 2.6 | 2.8 | · | 2.4 | |
| Quick Ratio | 2.5 | 2.3 | · | 2.3 | 2.2 | 2.4 | · | 2.1 | 1.9 | 1.9 | · | 1.7 | 1.6 | 1.8 | · | 1.5 |
Eficiência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 0.4 | 0.4 | · | 0.4 | 0.6 | 0.4 | · | 0.4 | 0.5 | 0.5 | · | 0.5 | 0.6 | 0.7 | · | 0.7 |
Avaliação (TTM) 9
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $210M | $210M | · | $207M | $225M | $208M | · | $232M | $270M | $289M | · | $322M | $350M | $365M | · | $421M | |
| Net Income TTM | $-40M | $-48M | · | $-63M | $-53M | $-49M | · | $-53M | $-45M | $-63M | · | $-58M | $-109M | $-123M | · | $-120M | |
| Market Cap | $6.70B | $6.07B | · | $6.81B | $6.74B | $3.73B | · | $5.18B | $5.67B | $7.31B | · | $7.52B | $9.71B | $12.22B | · | $8.80B | |
| P/E | -159.4 | -120.5 | · | -109.2 | -124.8 | -75.0 | · | -96.9 | -125.5 | -118.7 | · | -131.4 | -88.1 | -96.8 | · | -72.7 | |
| P/S | 31.9 | 29.0 | · | 33.0 | 30.0 | 17.9 | · | 22.3 | 21.0 | 25.3 | · | 23.3 | 27.7 | 33.5 | · | 20.9 | |
| P/B | 15.1 | 13.5 | · | 14.8 | 14.5 | 7.9 | · | 9.8 | 10.3 | 13.4 | · | 13.6 | 17.1 | 20.9 | · | 15.0 | |
| P / Tangible Book | 15.5 | 13.9 | · | 15.3 | 15.0 | 8.1 | · | 10.1 | 10.6 | 13.9 | · | 14.1 | 17.7 | 21.7 | · | 15.5 | |
| P / Cash Flow | · | 949.8 | · | · | · | -299.3 | · | · | · | -580.2 | · | · | · | -1743.4 | · | · | |
| Earnings Yield | -0.63% | -0.83% | · | -0.92% | -0.80% | -1.3% | · | -1.0% | -0.80% | -0.84% | · | -0.76% | -1.1% | -1.0% | · | -1.4% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $214M | $229M | $307M | $369M | $583M |
| Margem Bruta % | 56.6% | 35.6% | 53.9% | — | — |
| Margem Operacional % | -23.5% | -40.2% | -22.0% | — | — |
| Lucro líquido | $-39M | $-82M | $-59M | $-106M | $8M |
| EPS Diluído | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 3.3 | 3.3 | 2.8 | — | — |
| Índice de Liquidez Seca | 2.2 | 2.3 | 1.8 | — | — |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 90 declarantes · $59.1M total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 23 (+15 vs trimestre anterior) | 7 (-12 vs trimestre anterior) | 19 (+1 vs trimestre anterior) | 10 (-3 vs trimestre anterior) | +89K |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| Sarissa Capital Management LP | $26.673.916 | 1.673.395 | 45,11% | Ações |
| Kynam Capital Management, LP | $8.495.733 | 532.982 | 14,37% | Ações |
| Waterfront Wealth Inc. | $3.183.561 | 213.949 | 5,38% | Ações |
| Brooklands Fund Management Ltd | $2.741.449 | 177.325 | 4,64% | Ações |
| Eversept Partners, LP | $2.316.018 | 145.296 | 3,92% | Ações |
| MILLENNIUM MANAGEMENT LLC | $1.845.980 | 115.808 | 3,12% | Ações |
| TWO SIGMA INVESTMENTS, LP | $1.602.145 | 100.511 | 2,71% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $1.144.699 | 71.813 | 1,94% | Ações |
| CITADEL ADVISORS LLC | $971.671 | 60.958 | 1,64% | Ações |
| LCM Capital Management Inc | $818.710 | 51.362 | 1,38% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $771.002 | 48.369 | 1,30% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $765.120 | 48.000 | 1,29% | Opção de compra |
| George Kaiser Family Foundation | $593.080 | 37.207 | 1,00% | Ações |
| JANE STREET GROUP, LLC | $523.294 | 32.829 | 0,89% | Ações |
| TWO SIGMA ADVISERS, LP | $516.265 | 36.995 | 0,87% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $462.276 | 29.001 | 0,78% | Ações |
| STATE STREET CORP | $398.755 | 25.016 | 0,67% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $385.748 | 24.200 | 0,65% | Opção de venda |
| Bleakley Financial Group, LLC | $374.670 | 23.505 | 0,63% | Ações |
| State of New Jersey Common Pension Fund D | $300.931 | 18.879 | 0,51% | Ações |
| CITADEL ADVISORS LLC | $299.672 | 18.800 | 0,51% | Opção de venda |
| COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | $292.818 | 18.370 | 0,50% | Ações |
| R Squared Ltd | $269.992 | 16.938 | 0,46% | Ações |
| State of Tennessee, Department of Treasury | $239.164 | 15.004 | 0,40% | Ações |
| MORGAN STANLEY | $237.618 | 14.907 | 0,40% | Ações |
| Quadrature Capital Ltd | $236.581 | 14.842 | 0,40% | Ações |
| Quinn Opportunity Partners LLC | $228.022 | 14.305 | 0,39% | Ações |
| Cubist Systematic Strategies, LLC | $224.390 | 13.699 | 0,38% | Ações |
| EntryPoint Capital, LLC | $194.882 | 12.226 | 0,33% | Ações |
| Jump Financial, LLC | $191.407 | 12.008 | 0,32% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $187.629 | 11.771 | 0,32% | Ações |
| WELLS FARGO & COMPANY/MN | $179.564 | 11.265 | 0,30% | Ações |
| NJ State Employees Deferred Compensation Plan | $178.542 | 10.900 | 0,30% | Ações |
| Verdad Advisers, LP | $166.270 | 10.431 | 0,28% | Ações |
| CITADEL ADVISORS LLC | $164.182 | 10.300 | 0,28% | Opção de compra |
| Steward Partners Investment Advisory, LLC | $142.025 | 8.910 | 0,24% | Ações |
| NEW YORK STATE COMMON RETIREMENT FUND | $121.224 | 7.605 | 0,21% | Ações |
| OSAIC HOLDINGS, INC. | $104.537 | 6.559 | 0,18% | Ações |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $92.038 | 5.774 | 0,16% | Ações |
| MERCER GLOBAL ADVISORS INC /ADV | $80.099 | 5.025 | 0,14% | Ações |
| UBS Group AG | $67.171 | 4.214 | 0,11% | Ações |
| RHUMBLINE ADVISERS | $59.498 | 3.733 | 0,10% | Ações |
| NATIONAL BANK OF CANADA /FI/ | $40.137 | 2.518 | 0,07% | Ações |
| AMERIPRISE FINANCIAL INC | $30.318 | 1.902 | 0,05% | Ações |
| ROYAL BANK OF CANADA | $28.000 | 1.787 | 0,05% | Ações |
| GAMMA Investing LLC | $25.121 | 1.576 | 0,04% | Ações |
| RAYMOND JAMES FINANCIAL INC | $22.332 | 1.401 | 0,04% | Ações |
| NewEdge Advisors, LLC | $21.471 | 1.347 | 0,04% | Ações |
| Farther Finance Advisors, LLC | $15.271 | 958 | 0,03% | Ações |
| BlackRock, Inc. | $13.677 | 858 | 0,02% | Ações |
| IFP Advisors, Inc | $12.975 | 814 | 0,02% | Ações |
| Beaird Harris Wealth Management, LLC | $11.955 | 750 | 0,02% | Ações |
| ACADIAN ASSET MANAGEMENT LLC | $11.467 | 720.984 | 0,02% | Ações |
| CoreCap Advisors, LLC | $8.528 | 535 | 0,01% | Ações |
| Integrated Wealth Concepts LLC | $8.449 | 530 | 0,01% | Ações |
| JONES FINANCIAL COMPANIES LLLP | $7.844 | 493 | 0,01% | Ações |
| BARCLAYS PLC | $4.862 | 305 | 0,01% | Ações |
| JPMORGAN CHASE & CO | $3.853 | 242 | 0,01% | Ações |
| CWM, LLC | $3.644 | 252 | 0,01% | Ações |
| Westside Investment Management, Inc. | $3.268 | 205 | 0,01% | Ações |
| Global Retirement Partners, LLC | $2.646 | 166 | 0,00% | Ações |
| GROUP ONE TRADING LLC | $2.072 | 130 | 0,00% | Ações |
| HARBOUR INVESTMENTS, INC. | $1.562 | 98 | 0,00% | Ações |
| Federation des caisses Desjardins du Quebec | $1.435 | 90 | 0,00% | Ações |
| Activest Wealth Management | $797 | 50 | 0,00% | Ações |
| HighMark Wealth Management LLC | $797 | 50 | 0,00% | Ações |
| Arax Advisory Partners | $685 | 43 | 0,00% | Ações |
| Darwin Wealth Management, LLC | $398 | 25 | 0,00% | Ações |
| Continuum Advisory, LLC | $303 | 19 | 0,00% | Ações |
| Caitong International Asset Management Co., Ltd | $271 | 17 | 0,00% | Ações |
| SEI INVESTMENTS CO | $260 | 16 | 0,00% | Ações |
| Hayek Kallen Investment Management | $204 | 12.809 | 0,00% | Ações |
| Atlantic Union Bankshares Corp | $192 | 12 | 0,00% | Ações |
| Truvestments Capital LLC | $191 | 12 | 0,00% | Ações |
| Parallel Advisors, LLC | $159 | 10 | 0,00% | Ações |
| Creative Capital Management Investments LLC | $143 | 9 | 0,00% | Ações |
| Key Financial Inc | $128 | 8 | 0,00% | Ações |
| CITIGROUP INC | $128 | 8 | 0,00% | Ações |
| MCGUIRE CAPITAL ADVISORS INC | $112 | 7 | 0,00% | Ações |
| EASTERN BANK | $112 | 7 | 0,00% | Ações |
| Lindbrook Capital, LLC | $90 | 200 | 0,00% | Ações |
| Oakmont Advisory Group, LLC | $80 | 5 | 0,00% | Ações |
| Allworth Financial LP | $80 | 5 | 0,00% | Ações |
| Crewe Advisors LLC | $80 | 5 | 0,00% | Ações |
| BFSG, LLC | $80 | 5 | 0,00% | Ações |
| SBI Securities Co., Ltd. | $80 | 5 | 0,00% | Ações |
| WHITTIER TRUST CO | $63 | 4 | 0,00% | Ações |
| Caitlin John, LLC | $32 | 2 | 0,00% | Ações |
| WHITTIER TRUST CO OF NEVADA INC | $15 | 1 | 0,00% | Ações |
| JFS WEALTH ADVISORS, LLC | $15 | 1 | 0,00% | Ações |
Executivos da empresa 37 insiders · 17 diretores · 22 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Aaron Berg | President and CEO | 26 de Junho de 2026 M | 85.648 | 0 | 0 | $0 |
| Patrick Holt | President and CEO | 22 de Janeiro de 2024 P | 314.426 | 0 | 0 | $0 |
| Karim Mikhail | President and CEO | 21 de Fevereiro de 2023 A | 283.507 | 0 | 0 | $0 |
| John F Thero | President and CEO | 19 de Novembro de 2019 S | 2.342.285 | 0 | 0 | $0 |
| Peter L. Fishman | SVP, CFO | 1 de Agosto de 2026 A | 7.619 | 0 | 0 | $0 |
| Thomas Charles Reilly | EVP and CFO | 1 de Julho de 2024 M | 94.305 | 0 | 0 | $0 |
| Michael Wayne Kalb | SVP and CFO | 16 de Dezembro de 2019 M | 21.552 | 0 | 0 | $0 |
| David Paul Keenan | EVP, Chief Operating Officer | 1 de Julho de 2026 A | 13.470 | 0 | 0 | $0 |
| Jonathan Provoost | EVP, Chief Legal Officer | 1 de Julho de 2026 A | 4.624 | 0 | 0 | $0 |
| Steven B Ketchum | EVP, Chief Scientific Officer | 1 de Julho de 2026 A | 42.680 | 0 | 0 | $0 |
| Joseph T Kennedy | General Counsel | 7 de Outubro de 2019 F | 125.723 | 0 | 0 | $0 |
| Mark Salyer | Chief Commercial Officer | 1 de Fevereiro de 2018 A | — | 0 | 0 | $0 |
| Michael James Farrell | VP, Finance | 1 de Fevereiro de 2016 A | 30.190 | 0 | 0 | $0 |
| Paul Huff | Chief Commercial Officer | 26 de Julho de 2012 A | 0 | 0 | 0 | $0 |
| Stuart D Sedlack | Senior Vice President | 26 de Julho de 2012 A | 0 | 0 | 0 | $0 |
| Paresh Soni | SVP and Head of Development | 1 de Fevereiro de 2012 A | 0 | 0 | 0 | $0 |
| Frederick W Ahlholm | Vice President Finance | 1 de Fevereiro de 2012 A | 0 | 0 | 0 | $0 |
| Oliver O'Connor | Conselheiro | 18 de Abril de 2026 M | 801 | 0 | 0 | $0 |
| Paul Cohen | Conselheiro | 18 de Abril de 2026 M | 836 | 0 | 0 | $0 |
| Diane E. Sullivan | Conselheiro | 18 de Abril de 2026 M | 836 | 0 | 0 | $0 |
| Louis Sterling III | Conselheiro | 18 de Abril de 2026 M | 4.049 | 0 | 0 | $0 |
| Patrice Eadon Bonfiglio | Conselheiro | 18 de Abril de 2026 M | 836 | 0 | 0 | $0 |
| Keith Horn | Conselheiro | 18 de Abril de 2026 M | 836 | 0 | 0 | $0 |
| Odysseas D Kostas | Conselheiro | 18 de Abril de 2026 M | 836 | 0 | 0 | $0 |
| Mark Dipaolo | Conselheiro | 18 de Abril de 2025 M | 401 | 0 | 0 | $0 |
| Olsen Per Wold | Conselheiro | 10 de Janeiro de 2023 M | 171.027 | 0 | 0 | $0 |
| David M Stack | Conselheiro | 4 de Junho de 2021 P | 40.000 | 0 | 0 | $0 |
| Joseph S Zakrzewski | Conselheiro | 3 de Janeiro de 2020 M | 84.547 | 0 | 0 | $0 |
| Lars Ekman | Conselheiro | 12 de Novembro de 2019 M | 0 | 0 | 0 | $0 |
| Kristine Peterson | Conselheiro | 20 de Maio de 2019 A | 0 | 0 | 0 | $0 |
| Patrick J O'Sullivan | Conselheiro | 20 de Maio de 2019 A | — | 0 | 0 | $0 |
| VAN HEEK G JAN | Conselheiro | 20 de Maio de 2019 A | 14.168 | 0 | 0 | $0 |
| Dr. James I. Healy | Conselheiro | 11 de Julho de 2016 A | 90.000 | 0 | 0 | $0 |
| GORDON CARL L | Conselheiro | 4 de Setembro de 2012 S | 5.700 | 0 | 0 | $0 |
| Joseph Anderson | Conselheiro | 10 de Julho de 2012 A | 11.683 | 0 | 0 | $0 |
| David W Feigal Jr | Conselheiro | 12 de Julho de 2011 A | — | 0 | 0 | $0 |
| Abingworth LLP | Detentor de 10% | 19 de Abril de 2012 S | 1.599.168 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 34 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Sarissa Capital Management LP, Alexander J Denner ×3 declarações | 25 de Março de 2025 | 8,08% | Emenda | Campanha no conselho | SEC |
| 28 de Fevereiro de 2023 | — | Declaração inicial | — | SEC | |
| 27 de Fevereiro de 2023 | — | Declaração inicial | — | SEC | |
| 21 de Fevereiro de 2023 | — | Declaração inicial | — | SEC | |
| OR ×6 declarações | 15 de Fevereiro de 2023 | — | Declaração inicial | — | SEC |
| 14 de Fevereiro de 2023 | — | Declaração inicial | — | SEC | |
| 10 de Fevereiro de 2023 | — | Declaração inicial | — | SEC | |
| 19 de Janeiro de 2023 | — | Declaração inicial | — | SEC | |
| 16 de Junho de 2022 | — | Declaração inicial | — | SEC | |
| Sofinnova Venture Partners VII, L.P. (“SVP VII”), Sofinnova Management VII, L.L.C. (“SM VII”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Eric P. Buatois (“Buatois”) ×4 declarações | 23 de Agosto de 2013 | — | Declaração inicial | Investimento passivo | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures V Co-Invest Growth Equity Fund LP 98-057-9772, Abingworth Bioventures V L.P. 98-051-8587, Abingworth Bioequities Master Fund Limited 66-066-0960 ×10 declarações | 22 de Julho de 2013 | — | Declaração inicial | Campanha no conselho | SEC |
| Boxer Capital, LLC, Boxer Asset Management Inc., Joseph Lewis ×4 declarações | 24 de Agosto de 2011 | — | Declaração inicial | — | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP III LLC, Samuel D. Isaly ×14 declarações | 28 de Abril de 2011 | — | Declaração inicial | — | SEC |
| Fountain Healthcare Partners Fund 1, L.P. (“ Fountain ”), Fountain Healthcare Partners Ltd., Manus Rogan, Aidan King, Ena Prosser, Justin Lynch ×2 declarações | 10 de Dezembro de 2010 | — | Declaração inicial | — | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) | 26 de Outubro de 2010 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.